Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

Key Takeaway: SI-BONE, Inc. will present at the Jefferies London Healthcare Conference on November 15, 2023. The company will host a fireside chat aimed at engaging investors. SI-BONE is recognized for its advancements in minimally invasive treatments for musculoskeletal disorders. The live audio of the session will be accessible through their website, with recordings available afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE will participate in an important healthcare conference.
  • The company has a strong history of innovation in minimally invasive surgeries.
  • Successful hosting of a live chat could enhance investor relations.
  • Over 85,000 procedures performed indicate significant market penetration.

Full Press Release Details

SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Jefferies London Healthcare Conference in London, UK. Management will be hosting a fireside chat on Wednesday, November 15, 2023, at 4:00 a.m. Eastern Time / 1:00 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/jeff287/sibn/1855312. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 85,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Sr. Director, FP&A and Investor Relations

Frequently Asked Questions

What event will SI-BONE participate in on November 15, 2023?

SI-BONE will participate in the Jefferies London Healthcare Conference.

How can I listen to the SI-BONE conference call?

You can listen by registering at the provided link or visiting their website.

What is SI-BONE known for?

SI-BONE is a leader in surgical treatments for sacropelvic musculoskeletal disorders.

How many procedures has SI-BONE supported?

SI-BONE has supported over 85,000 sacropelvic procedures since 2009.

Where can I find more information on SI-BONE?

More information is available on SI-BONE’s official website.

Last updated: Nov 1, 2023